About - REGN :

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Employees - 14165, CEO - Dr. Leonard S. Schleifer M.D., Ph.D., Sector - Healthcare, Country - US, Market Cap - 76.43B

Altman ZScore(max is 10): 8.01, Piotroski Score(max is 10): 4, Working Capital: $15672600000, Total Assets: $37441900000, Retained Earnings: $30755200000, EBIT: 4361700000, Total Liabilities: $8116000000, Revenue: $13847100000

- Current Price $701.85 - Analyst Target Price $1074.73

Stats & Key Metrics
TickerREGN
IndexNDX, S&P 500
Curent Price 701.85
Change-0.90%
Market Cap76.43B
Average Volume850.56K
Income4.65B
Sales13.85B
Book Value/Share266.36
Cash/Share89.96
Dividend Est-
Dividend TTM-
Dividend Ex-Date-
Employees13450
Moving Avg 20days-6.16%
Moving Avg 50days-15.05%
Moving Avg 200days-28.46%
Shares Outstanding108.30M
Earnings DateOct 31 BMO
Inst. Ownership85.68%
Key Ratios & Margins
Price/Earnings17.37
Forwad P/E15.69
PE Growth2.67
Price/Sales5.52
Price/Book2.63
Price/Cash7.80
Price/FCF22.22
Quick Ratio4.46
Current Ratio5.28
Debt/Equity0.09
Return on Assets13.37%
Return on Equity17.17%
Return on Investment14.53%
Gross Margin82.74%
Ops Margin29.89%
Profit Margin33.61%
RSI27.80
BETA(β)0.09
From 52week Low1.28%
From 52week High-42.05%
Earnings & Valuation
EPS40.41
EPS next Year44.75
EPS next Qtr11.30
EPS this Year2.79%
EPS next 5 Year6.50%
EPS past 5 Year10.31%
Sales past 5 Year19.99%
EPS Y/Y15.72%
Sales Y/Y5.72%
EPS Q/Q29.82%
Sales Q/Q10.65%
Sales Surprise1.25%
EPS Surprise6.54%
ATR(14)21.14
Perf Week-4.03%
Perf Month-5.58%
Perf Quarter-35.73%
Perf Year-16.62%
Perf YTD-20.09%
Target Price1074.73

AryaFin Engine© - An AI FinTech Venture - 2024 Disclaimer